RESUMO
Heterozygous RTN2 variants have been previously identified in a limited cohort of families affected by autosomal dominant spastic paraplegia (SPG12-OMIM:604805) with a variable age of onset. Nevertheless, the definitive validity of SPG12 remains to be confidently confirmed due to the scarcity of supporting evidence. In this study, we identified and validated seven novel or ultra-rare homozygous loss-of-function RTN2 variants in 14 individuals from seven consanguineous families with distal hereditary motor neuropathy (dHMN) using exome, genome and Sanger sequencing coupled with deep-phenotyping. All affected individuals (seven males and seven females, aged 9-50â years) exhibited weakness in the distal upper and lower limbs, lower limb spasticity and hyperreflexia, with onset in the first decade of life. Nerve conduction studies revealed axonal motor neuropathy with neurogenic changes in the electromyography. Despite a slowly progressive disease course, all patients remained ambulatory over a mean disease duration of 19.71 ± 13.70â years. Characterization of Caenorhabditis elegans RTN2 homologous loss-of-function variants demonstrated morphological and behavioural differences compared with the parental strain. Treatment of the mutant with an endoplasmic/sarcoplasmic reticulum Ca2+ reuptake inhibitor (2,5-di-tert-butylhydroquinone) rescued key phenotypic differences, suggesting a potential therapeutic benefit for RTN2-disorder. Despite RTN2 being an endoplasmic reticulum (ER)-resident membrane shaping protein, our analysis of patient fibroblast cells did not find significant alterations in ER structure or the response to ER stress. Our findings delineate a distinct form of autosomal recessive dHMN with pyramidal features associated with RTN2 deficiency. This phenotype shares similarities with SIGMAR1-related dHMN and Silver-like syndromes, providing valuable insights into the clinical spectrum and potential therapeutic strategies for RTN2-related dHMN.
Assuntos
Linhagem , Humanos , Masculino , Feminino , Criança , Adulto , Adolescente , Adulto Jovem , Pessoa de Meia-Idade , Animais , Extremidade Inferior/fisiopatologia , Caenorhabditis elegans , Espasticidade Muscular/genética , Espasticidade Muscular/fisiopatologia , Paraplegia Espástica Hereditária/genética , Paraplegia Espástica Hereditária/fisiopatologia , MutaçãoRESUMO
Spasticity, affecting â¼75% of patients with spinal cord injury (SCI), leads to hyperreflexia, muscle spasms, and cocontractions of antagonist muscles, greatly affecting their quality of life. Spasticity primarily stems from the hyperexcitability of motoneurons below the lesion, driven by an upregulation of the persistent sodium current and a downregulation of chloride extrusion. This imbalance results from the post-SCI activation of calpain1, which cleaves Nav1.6 channels and KCC2 cotransporters. Our study was focused on mitigating spasticity by specifically targeting calpain1 in spinal motoneurons. We successfully transduced lumbar motoneurons in adult rats with SCI using intrathecal administration of adeno-associated virus vector serotype 6, carrying a shRNA sequence against calpain1. This approach significantly reduced calpain1 expression in transduced motoneurons, leading to a noticeable decrease in spasticity symptoms, including hyperreflexia, muscle spasms, and cocontractions in hindlimb muscles, which are particularly evident in the second month post-SCI. In addition, this decrease, which prevented the escalation of spasticity to a severe grade, paralleled the restoration of KCC2 levels in transduced motoneurons, suggesting a reduced proteolytic activity of calpain1. These findings demonstrate that inhibiting calpain1 in motoneurons is a promising strategy for alleviating spasticity in SCI patients.
Assuntos
Traumatismos da Medula Espinal , Simportadores , Animais , Ratos , Neurônios Motores/metabolismo , Espasticidade Muscular/genética , Espasticidade Muscular/terapia , Qualidade de Vida , Reflexo Anormal , Espasmo/metabolismo , Espasmo/patologia , Medula Espinal/metabolismo , Traumatismos da Medula Espinal/complicações , Traumatismos da Medula Espinal/genética , Traumatismos da Medula Espinal/terapia , Simportadores/genéticaRESUMO
Mutations in the SACS gene are associated with autosomal recessive spastic ataxia of Charlevoix-Saguenay disease (ARSACS) or complex clinical phenotypes of Charcot-Marie-Tooth disease (CMT). This study aimed to identify SACS mutations in a Korean CMT cohort with cerebellar ataxia and spasticity by whole exome sequencing (WES). As a result, eight pathogenic SACS mutations in four families were identified as the underlying causes of these complex phenotypes. The prevalence of CMT families with SACS mutations was determined to be 0.3%. All the patients showed sensory, motor, and gait disturbances with increased deep tendon reflexes. Lower limb magnetic resonance imaging (MRI) was performed in four patients and all had fatty replacements. Of note, they all had similar fatty infiltrations between the proximal and distal lower limb muscles, different from the neuromuscular imaging feature in most CMT patients without SACS mutations who had distal dominant fatty involvement. Therefore, these findings were considered a characteristic feature in CMT patients with SACS mutations. Although further studies with more cases are needed, our results highlight lower extremity MRI findings in CMT patients with SACS mutations and broaden the clinical spectrum. We suggest screening for SACS in recessive CMT patients with complex phenotypes of ataxia and spasticity.
Assuntos
Doença de Charcot-Marie-Tooth , Heterozigoto , Espasticidade Muscular , Mutação , Humanos , Masculino , Doença de Charcot-Marie-Tooth/genética , Feminino , Adulto , República da Coreia/epidemiologia , Espasticidade Muscular/genética , Espasticidade Muscular/diagnóstico por imagem , Estudos de Coortes , Pessoa de Meia-Idade , Imageamento por Ressonância Magnética , Proteínas de Choque Térmico/genética , Linhagem , Sequenciamento do Exoma , Ataxia Cerebelar/genética , Ataxia Cerebelar/diagnóstico por imagem , Fenótipo , Adolescente , Adulto JovemRESUMO
Objective: To explore the diagnosis and treatment of adolescence-onset methylenetetrahydrofolate reductase (MTHFR) deficiency. Methods: This was a retrospective case study. Nine patients with adolescence-onset MTHFR deficiency were diagnosed at Peking University First Hospital from January 2016 to December 2022, and followed up for more than 1 year. Their general information, clinical manifestations, laboratory tests, cranial images, MTHFR gene variants, diagnosis, treatment, and outcome were analyzed retrospectively. Results: The 9 patients came from 8 families. They had symptoms at age of 8.0 years to 17.0 years and diagnosed at 9.0 years to 17.5 years. Eight were male and 1 was female. Two patients were brothers, the elder brother developed abnormal gait at 17.0 years; and the younger brother was then diagnosed at 15.0 years of age and treated at the asymptomatic stage, who was 18.0 years old with normal condition during this study. The main manifestations of the 8 symptomatic patients included progressive dyskinesia and spastic paralysis of the lower limbs, with or without intellectual decline, cognitive impairment and behavioral abnormalities. Totally, 15 variants of MTHFR gene were identified in the 9 patients, including 8 novel variants. Five patients had brain image abnormalities. Increased plasma total homocysteine level (65-221 µmol/L) was found in all patients, and decreased to 20-70 µmol/L after treatment with betaine and calcium folinate. Besides, the 8 symptomatic patients had their behavior and cognitive problems significantly improved, with a legacy of lower limb motor disorders. Conclusions: Late-onset MTHFR deficiency can occur in adolescence. The diagnosis is usually delayed because of non-specific clinical symptoms. The test of blood total homocysteine could be used as a selective screening test. Eight novel varients of MTHFR gene were identified. Timely treatment can improve clinical condition significantly, and pre-symptomatic treatment may prevent brain damage.
Assuntos
Metilenotetra-Hidrofolato Redutase (NADPH2) , Espasticidade Muscular , Adolescente , Criança , Feminino , Humanos , Masculino , Homocisteína/uso terapêutico , Homocistinúria , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Metilenotetra-Hidrofolato Redutase (NADPH2)/deficiência , Espasticidade Muscular/diagnóstico , Espasticidade Muscular/genética , Espasticidade Muscular/tratamento farmacológico , Transtornos Psicóticos , Estudos RetrospectivosRESUMO
Spastic Ataxias (SA) are a group of neurodegenerative disorders with combined pyramidal and cerebellar system affection, leading to an overlap phenotype between Hereditary Spastic Paraplegias (HSP) and Cerebellar Ataxias (CA). Here we describe the generation of iPSCs from three unrelated patients with an ultra-rare subtype of SA caused by compound heterozygous mutations in POLR3A, that encodes the largest subunit of RNA polymerase III. iPSCs were reprogrammed from normal human dermal fibroblasts (NHDFs) using episomal reprogramming with integration-free plasmid vectors: HIHRSi004-A, derived from a 44 year-old male carrying the mutations c.1909 + 22G > A/c.3944_3945delTG, HIHRSi005-A obtained from a 66 year-old male carrying the mutations c.1909 + 22G > A/c.1531C > T, and HIHRSi006-A from a 27 year-old male carrying the mutations c.1909 + 22G > A/c.2472_2472delC (ENST00000372371.8).
Assuntos
Células-Tronco Pluripotentes Induzidas , Deficiência Intelectual , Atrofia Óptica , Ataxias Espinocerebelares , Adulto , Idoso , Humanos , Masculino , Linhagem Celular , Células-Tronco Pluripotentes Induzidas/metabolismo , Espasticidade Muscular/genética , Mutação , RNA Polimerase III/genética , RNA Polimerase III/metabolismo , Ataxias Espinocerebelares/genéticaRESUMO
We present an infant referred to Developmental Paediatrics for delays, slow growth, hypotonia, esotropia and spasticity. Over the course of 2 months, the infant's exam progressed, demonstrating worsening spasticity and tonal changes in the setting of a normal brain MRI with acquired microcephaly. Genetic testing demonstrated a pathogenic CTNNB1 nonsense mutation. Following the discovery of the underlying cause for the child's clinical picture, the child was evaluated by therapeutic services and neurology, which was initially only available via asynchronous telehealth, due to a resource limited area. Cerebral palsy is a nonprogressive neurodevelopmental disorder and, when associated with developmental delay, qualifies for further genetic investigation into the underlying aetiology. Genetic testing recommendations exist for developmental delay, but there is no current algorithm regarding testing for cerebral palsy. Education and clear guidelines on genetic testing allow for better prognostication and potential treatment in cases of cerebral palsy, especially when associated with other disorders.
Assuntos
Paralisia Cerebral , Deficiências do Desenvolvimento , Espasticidade Muscular , beta Catenina , Humanos , Espasticidade Muscular/genética , Espasticidade Muscular/diagnóstico , Lactente , Deficiências do Desenvolvimento/genética , Paralisia Cerebral/genética , beta Catenina/genética , Masculino , Códon sem Sentido , Feminino , Imageamento por Ressonância Magnética , Testes GenéticosRESUMO
Intellectual disability (ID), which affects around 2% to 3% of the population, accounts for 0.63% of the overall prevalence of neurodevelopmental disorders (NDD). ID is characterized by limitations in a person's intellectual and adaptive functioning, and is caused by pathogenic variants in more than 1000 genes. Here, we report a rare missense variant (c.350T>C; p.(Leu117Ser)) in HACE1 segregating with NDD syndrome with clinical features including ID, epilepsy, spasticity, global developmental delay, and psychomotor impairment in two siblings of a consanguineous Pakistani kindred. HACE1 encodes a HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1), which is involved in protein ubiquitination, localization, and cell division. HACE1 is also predicted to interact with several proteins that have been previously implicated in the ID phenotype in humans. The p.(Leu117Ser) variant replaces an evolutionarily conserved residue of HACE1 and is predicted to be deleterious by various in silico algorithms. Previously, eleven protein truncating variants of HACE1 have been reported in individuals with NDD. However, to our knowledge, p.(Leu117Ser) is the second missense variant in HACE1 found in an individual with NDD.
Assuntos
Epilepsia , Deficiência Intelectual , Espasticidade Muscular , Mutação de Sentido Incorreto , Linhagem , Ubiquitina-Proteína Ligases , Humanos , Deficiência Intelectual/genética , Deficiência Intelectual/patologia , Ubiquitina-Proteína Ligases/genética , Masculino , Feminino , Epilepsia/genética , Paquistão , Espasticidade Muscular/genética , Transtornos Psicomotores/genética , Transtornos Psicomotores/patologia , Criança , Pré-EscolarRESUMO
The aim of this study was to develop a model to predict individual subject disease trajectories including parameter uncertainty and accounting for missing data in rare neurological diseases, showcased by the ultra-rare disease Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS). We modelled the change in SARA (Scale for Assessment and Rating of Ataxia) score versus Time Since Onset of symptoms using non-linear mixed effect models for a population of 173 patients with ARSACS included in the prospective real-world multicenter Autosomal Recessive Cerebellar Ataxia (ARCA) registry. We used the Multivariate Imputation Chained Equation (MICE) algorithm to impute missing covariates, and a covariate selection procedure with a pooled p-value to account for the multiply imputed data sets. We then investigated the impact of covariates and population parameter uncertainty on the prediction of the individual trajectories up to 5 years after their last visit. A four-parameter logistic function was selected. Men were estimated to have a 25% lower SARA score at disease onset and a moderately higher maximum SARA score, and time to progression (T50) was estimated to be 35% lower in patients with age of onset over 15 years. The population disease progression rate started slowly at 0.1 points per year peaking to a maximum of 0.8 points per year (at 36.8 years since onset of symptoms). The prediction intervals for SARA scores 5 years after the last visit were large (median 7.4 points, Q1-Q3: 6.4-8.5); their size was mostly driven by individual parameter uncertainty and individual disease progression rate at that time.
Assuntos
Progressão da Doença , Espasticidade Muscular , Ataxias Espinocerebelares , Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Espasticidade Muscular/genética , Estudos Prospectivos , Doenças Raras/genética , Sistema de Registros , Índice de Gravidade de Doença , Ataxias Espinocerebelares/genética , Ataxias Espinocerebelares/congênito , Incerteza , Recém-Nascido , Lactente , Pré-EscolarRESUMO
While biallelic POLR3A loss-of-function variants are traditionally linked to hypomyelinating leukodystrophy, patients with a specific splice variant c.1909+22G>A manifest as adolescent-onset spastic ataxia without overt leukodystrophy. In this study, we reported eight new cases, POLR3A-related disorder with c.1909+22 variant. One of these patients showed expanded phenotypic spectrum of generalised dystonia and her sister remained asymptomatic except for hypodontia. Two patients with dystonic arm tremor responded to deep brain stimulation. In our systemic literature review, we found that POLR3A-related disorder with c.1909+22 variant has attenuated disease severity but frequency of dystonia and upper limb tremor did not differ among genotypes.
Assuntos
Estimulação Encefálica Profunda , Distonia , RNA Polimerase III , Humanos , Feminino , RNA Polimerase III/genética , Distonia/genética , Distonia/terapia , Adolescente , Masculino , Espasticidade Muscular/genética , Espasticidade Muscular/terapia , Adulto , Ataxias Espinocerebelares/genética , Ataxias Espinocerebelares/terapia , Ataxias Espinocerebelares/fisiopatologia , Adulto Jovem , Criança , Deficiência Intelectual , Atrofia ÓpticaRESUMO
BACKGROUND: Autosomal recessive spastic ataxia ofCharlevoix-Saguenay (ARSACS) is a rare neurodegenerative disorder characterizedby early-onset cerebellar ataxia, peripheral sensorimotor neuropathy, and lowerlimb spasticity. We present clinical andgenetic data of the first Bulgarian patients diagnosed with ARSACS by wholeexome sequencing (WES). METHODS: Variant filtering was performed usinglocally established pipeline and the selected variants were analysed by Sangersequencing. All patients underwent clinical examination and testingincluding the standard rating scales for spastic paraplegia and ataxia. RESULTS: Five different SACS gene variants, three of which novel, have been identified inpatients from three different ethnic groups. In addition to the classicalclinical triad, brain MRI revealed cerebellar atrophy, linear pontineT2-hypointensities, and hyperintense rim lateral tothalamus combined with retinal nerve fiber layer thickening on opticcoherence tomography (OCT). CONCLUSION: We expand the mutation, geographic, and phenotypic spectrum of ARSACS, adding Bulgaria to the world map of the disease, and drawing attention to the fact that it is still misdiagnosed. We demonstrated that brain MRI and OCT are necessary clinical tests for ARSACS diagnosis, even if one of the cardinal clinical features is lacking.
Assuntos
Proteínas de Choque Térmico , Espasticidade Muscular , Ataxias Espinocerebelares , Humanos , Masculino , Bulgária , Ataxias Espinocerebelares/genética , Ataxias Espinocerebelares/patologia , Ataxias Espinocerebelares/congênito , Feminino , Espasticidade Muscular/genética , Espasticidade Muscular/patologia , Espasticidade Muscular/diagnóstico , Espasticidade Muscular/diagnóstico por imagem , Proteínas de Choque Térmico/genética , Fenótipo , Criança , Adulto , Mutação , Adolescente , Imageamento por Ressonância MagnéticaRESUMO
Resumen: Introducción: La trombosis senovenosa cerebral neonatal (TSVC), es una patología rara y generalmente grave, de la cual se conoce poco sobre los mecanismos fisiopatológicos responsables y, aunque controvertido, se ha sugerido que la trombofilia genética, puede desempeñar un rol en la patogénesis. Debido a los temores de un sangrado intracraneal el tratamiento anticoagulante con heparina de bajo peso mole cular es controvertido. Objetivo: presentar un recién nacido con una trombosis senovenosa cerebral neonatal, discutir los factores de riesgo trombofílico, y el manejo con heparina de bajo peso molecu lar de la trombosis venosa cerebral. Caso Clínico: Recién nacido de término que debutó a los 8 días de vida con convulsiones clónicas, rechazo al pecho más hipoactividad motora. La neuroimagen con RM mostró una TSVC involucrando múltiples senos venosos, un infarto hemorrágico talámico dere cho y congestión venosa de la sustancia blanca frontal. El estudio de trombofilia puso de relieve una mutación homocigota del gen MTHFR C677T. El tratamiento con heparina de bajo peso molecular se asoció a repermeabilización del seno sagital superior a los 23 días de iniciada la terapia. Conclusio nes: La presentación clínica de la TSVC en el neonato es inespecífica, probablemente en relación con la extensión y gravedad de la lesión y el desarrollo de complicaciones asociadas, como infartos he morrágicos venosos intraparenquimatosos o hemorragia intraventricular. Estas complicaciones son detectables mediante Ecografia o Resonancia Magnética, y deben hacer sospechar una TSVC. En esta experiencia el tratamiento anticoagulante mostró ser seguro y prevenir la extensión de la trombosis.
Abstract: Introduction: Neonatal cerebral sinovenous thrombosis (CSNT) is a rare and generally serious con dition about which there is little knowledge of the responsible pathophysiological mechanisms and, although controversial, it has been suggested that genetic thrombophilia may play a role in its patho genesis. Out of concern for intracranial bleeding, the anticoagulant treatment with low-molecular- weight heparin is controversial. Objective: To present a case of a newborn with neonatal CSNT, to analyze the thrombophilic risk factors, and the management of cerebral venous thrombosis with low-molecular-weight heparin. Clinical Case: Full-term newborn who presented at eight days of life breastfeeding rejection, clonic seizures, and locomotor hypoactivity. The MRI neuroimaging showed a CSNT involving multiple venous sinuses, a right thalamic hemorrhagic infarction, and venous congestion in frontal white matter. Thrombophilia study highlighted a homozygous MTHFR C677T mutation. Treatment with low-molecular-weight heparin was associated with repermeabilization of the superior sagittal sinus after 23 days of starting therapy. Conclusions: The clinical presentation of CSNT in the neonate is nonspecific, probably related to the extent and severity of the injury and the development of associated complications, such as venous hemorrhagic infarctions and intraparenchymal or intraventricular hemorrhage. These complications are detected through ultrasound or MRI, and they should make us suspect a CSNT. In this experience, the anticoagulant treatment proved to be safe and prevents thrombus propagation.
Assuntos
Humanos , Feminino , Recém-Nascido , Trombose dos Seios Intracranianos/diagnóstico , Trombose dos Seios Intracranianos/etiologia , Enoxaparina/uso terapêutico , Metilenotetra-Hidrofolato Redutase (NADPH2)/deficiência , Homocistinúria/diagnóstico , Espasticidade Muscular/diagnóstico , Anticoagulantes/uso terapêutico , Transtornos Psicóticos/complicações , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/genética , Trombose dos Seios Intracranianos/tratamento farmacológico , Marcadores Genéticos , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Homocistinúria/complicações , Homocistinúria/genética , Homozigoto , Espasticidade Muscular/complicações , Espasticidade Muscular/genética , MutaçãoRESUMO
ABSTRACT Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset, neurodegenerative disorder caused by mutations in SACS, firstly reported in Quebec, Canada. The disorder is typically characterized by childhood onset ataxia, spasticity, neuropathy and retinal hypermyelination. The clinical picture of patients born outside Quebec, however, is often atypical. In the present article, the authors describe clinical and neuroradiological findings that raised the suspicion of an ARSACS diagnosis in two female cousins with Germanic background from Rio Grande do Sul, Brazil. We present a review on the neuroimaging, ophthalmologic and neurophysiologic clues for ARSACS diagnosis. The early-onset, slowly progressive, spastic-ataxia phenotype of reported patients was similar to ARSACS patients from Quebec. The SACS sequencing revealed the novel homozygous c.5150_5151insA frameshift mutation confirming the ARSACS diagnosis. ARSACS is a frequent cause of early onset ataxia/spastic-ataxia worldwide, with unknown frequency in Brazil.
RESUMO A ataxia espástica autossômica recessiva de Charlevoix-Saguenay (ARSACS) é uma doença neurodegenerativa de início precoce causada por mutações no gene SACS que foi inicialmente descrita na região de Quebec, Canadá. A apresentação típica de ARSACS é caracterizada por ataxia, espasticidade, polineuropatia e hipermielinização das fibras nervosas da retina de início infantil. No presente artigo, descrevemos os achados clínicos e neurorradiológicos que levaram à suspeita de ARSACS em duas primas descendentes de alemães naturais do Rio Grande do Sul, Brasil e revisamos os achados de neuroimagem, oftalmológicos e neurofisiológicos de ARSACS. O fenótipo de ataxia-espástica de início infantil precoce apresentado pelas pacientes era similar ao classicamente descrito em Quebec. O sequenciamento do SACS revelou a mutação nova c.5150_5151insA (mudança na matriz de leitura), em homozigose, confirmando o diagnóstico de ARSACS. A ARSACS é uma causa frequente de ataxia/ataxia-espástica de início precoce mundialmente, entretanto sua frequência é desconhecida no Brasil.
Assuntos
Humanos , Feminino , Adulto , Ataxias Espinocerebelares/congênito , Proteínas de Choque Térmico/genética , Espasticidade Muscular/genética , Espasticidade Muscular/diagnóstico por imagem , Mutação/genética , Linhagem , Fenótipo , Brasil , Imageamento por Ressonância Magnética , Ataxias Espinocerebelares/genética , Ataxias Espinocerebelares/diagnóstico por imagemAssuntos
Humanos , Anestésicos Inalatórios/efeitos adversos , Metilenotetra-Hidrofolato Redutase (NADPH2)/deficiência , Homocistinúria/diagnóstico , Anestesia , Espasticidade Muscular/diagnóstico , Óxido Nitroso/efeitos adversos , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/genética , 5-Metiltetra-Hidrofolato-Homocisteína S-Metiltransferase/antagonistas & inibidores , Cuidados Pré-Operatórios , Hiper-Homocisteinemia/complicações , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Homocisteína S-Metiltransferase/metabolismo , Homocistinúria/genética , Espasticidade Muscular/genética , MutaçãoRESUMO
Las fumonisinas son una familia de micotoxinas que contaminan al maíz, alteran el metabolismo de los esfingolípidos y del folato, se asocian con defectos del tubo neural y están catalogadas por la Agencia Internacional de Investigación en Cáncer (IARC por sus siglas en inglés) como posibles carcinógenos humanos. Debido a que en México los derivados de maíz constituyen una parte importante de la dieta y existe alta prevalencia de población genéticamente susceptible a la deficiencia de folato, en este ensayo se presentan las evidencias mundiales y nacionales de la exposición a fumonisinas y la relevancia que para México representa la evaluación de esta exposición.
Fumonisins are mycotoxins that contaminate maize, disrupt the folate and sphingolipid metabolism, are associated with neural tube defects, and are considered by the International Agency for Research on Cancer (IARC) as possible human carcinogens. Since maize-based foods are significant components of the Mexican diet and there is a high prevalence of genetic susceptibility for folate deficiency among Mexicans, this essay presents international and national evidence of fumonisin exposure and the relevance that such exposure represents for Mexico.
Assuntos
Adolescente , Adulto , Animais , Feminino , Humanos , Masculino , Camundongos , Gravidez , Ratos , Adulto Jovem , Ácido Fólico/metabolismo , Contaminação de Alimentos , Fumonisinas/efeitos adversos , Defeitos do Tubo Neural/etiologia , Carcinógenos Ambientais/efeitos adversos , Neoplasias do Sistema Digestório/induzido quimicamente , Neoplasias do Sistema Digestório/epidemiologia , Equidae , /antagonistas & inibidores , Fumonisinas/química , Fumonisinas/farmacocinética , Fumonisinas/toxicidade , Homocistinúria/epidemiologia , Homocistinúria/genética , Necrose Tubular Aguda/induzido quimicamente , Leucoencefalopatias/induzido quimicamente , Leucoencefalopatias/veterinária , Proteínas de Membrana Transportadoras/metabolismo , /deficiência , /genética , México , Espasticidade Muscular/epidemiologia , Espasticidade Muscular/genética , Defeitos do Tubo Neural/induzido quimicamente , Defeitos do Tubo Neural/epidemiologia , Defeitos do Tubo Neural/genética , Transtornos Psicóticos/epidemiologia , Transtornos Psicóticos/genética , Esfingolipídeos/química , Esfingolipídeos/metabolismo , Suínos , Teratogênicos/toxicidade , Adulto Jovem , Zea mays/microbiologiaRESUMO
Un varón de 40 años se internó por dificultad creciente para la marcha que había comenzado 2 años antes y que lo había reducido a una silla o a la cama. Hacía 7 años se le había diagnosticado enfermedad de Addison y tomaba regularmente 20 mg/día de hidrocortisona oral. Su padre, un tío paterno y 2 hermanas están sanos; un hermano afectado por oligofrenia, disartria y dificultad para caminar falleció a los 9 años de edad. A su ingreso, el paciente estaba lúcido y orientado,; tenía hiperpigmentaciín leve de piel y mucosas, alopecía en cuero cabeludo y cola de cejas, testículos de 3,5 ml y paraplejía espástica; los miembros inferiores conservaban la sensibilidad táctil y dolorosa. La radiografía de tórax y la reacción de Mantoux eran normales. Las pruebas hormonales de laboratorio confirmaron la insuficiencia suprarrenal primaria (con conservación de la función de la zona glomerulosa) y un hipogonadismo primario; la función tiroidea era normal. La velocidad de conducción motora en miembros inferiores era baja (30-32 m/seg), con aumento de las latencias proximal y distal; esto y el EMG eran compatibles con polineuropatía de tipo mielinopático. Se comprobó leve atrofia cortical difusa (TAC) de cráneo); los potenciales evocados auditivos de tronco cerebral mostraron baja amplitud del complejo IV-V y tiempo de conducción central prolongado (5,3 mseg). Los ácidos grasos séricos eran cuantitativa y cualitativamente normales por cromatografía gaseosa. En la biopsia de nervio safeno se observó desmielinización segmentaria y degeneración axonal, sin infiltrados inflamatorios; el estudio ultraestructural demostró, en el citoplasma de algunas células de Schwann, inclusiones bilaminares, en su mayoría curvalíneas, que confirmaron el diagnósticos clínico de adrenomieloneuropatía. Esta rara enfermedad familiar de transmisión recesiva ligada al cromosoma X se origina en un trastorno del metabolismo de los ácidos grasos saturados de cadena muy larga, con compromiso funcional del sistema nervioso y de células productoras de hormonas esteroides
Assuntos
Insuficiência Adrenal/complicações , Paraplegia/genética , Insuficiência Adrenal/diagnóstico , Adrenoleucodistrofia/diagnóstico , Diagnóstico Diferencial , Ácidos Graxos/metabolismo , Espasticidade Muscular/genética , Bainha de Mielina/ultraestrutura , Veia Safena/patologia , Testículo/patologiaRESUMO
La espasticidad es aún un desafío a médicos y científicos. Revisamos aquí los conceptos modernos acerca del compromiso de las fibras aferentes la II, III y IV así como también de aquellas que participan en la inhibición presináptica, la modulación de las células de Renshaw e hiperexcitabilidad de las motoneuronas alfa y gama que tienen que ver con este problema médico. Los estudios neurofisiológicos más comunes para evalaur la espasticidad humana son brevemente discutidos